更正：固定剂量复方药丸（多效药丸）在心血管疾病一级和二级预防中的成本效益：一项系统文献综述。
Correction: Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
作者信息
Jahangiri Reza, Rezapour Aziz, Malekzadeh Reza, Olyaeemanesh Alireza, Roshandel Gholamreza, Motevalian Seyed Abbas
出版信息
PLoS One. 2023 Oct 18;18(10):e0293219. doi: 10.1371/journal.pone.0293219. eCollection 2023.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0271908.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0271908。]
相似文献
1
Correction: Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.更正：固定剂量复方药丸（多效药丸）在心血管疾病一级和二级预防中的成本效益：一项系统文献综述。
PLoS One. 2023 Oct 18;18(10):e0293219. doi: 10.1371/journal.pone.0293219. eCollection 2023.
2
Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.固定剂量复方制剂（波利维）在心血管疾病一级和二级预防中的成本效益：系统文献回顾。
PLoS One. 2022 Jul 28;17(7):e0271908. doi: 10.1371/journal.pone.0271908. eCollection 2022.
3
Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.固定剂量复方制剂在中国、印度、墨西哥、尼日利亚和南非用于心血管疾病二级预防的成本效益：一项建模研究。
Lancet Glob Health. 2019 Oct;7(10):e1346-e1358. doi: 10.1016/S2214-109X(19)30339-0. Epub 2019 Aug 30.
4
Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.固定剂量复方制剂（复方药）在印度心血管疾病二级预防中的成本效益：UMPIRE 试验的试验内成本效益分析。
Int J Cardiol. 2018 Jul 1;262:71-78. doi: 10.1016/j.ijcard.2018.03.082. Epub 2018 Mar 21.
5
Correction: An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.更正：一项针对心血管疾病风险升高人群的四成分复方药丸（“多效药丸”）的国际随机安慰剂对照试验。
PLoS One. 2019 Nov 25;14(11):e0225924. doi: 10.1371/journal.pone.0225924. eCollection 2019.
6
Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill.高血压患者心血管疾病的多因素预防：心血管复方制剂
Curr Hypertens Rep. 2016 Apr;18(5):40. doi: 10.1007/s11906-016-0648-3.
7
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.新型心血管疾病二级预防治疗策略：成本效益的系统评价
Pharmacoeconomics. 2020 Oct;38(10):1095-1113. doi: 10.1007/s40273-020-00936-0.
8
Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.在英国使用复方制剂提高依从性对继发性心血管疾病预防的成本效益及公共卫生效益
BMJ Open. 2015 May 9;5(5):e007111. doi: 10.1136/bmjopen-2014-007111.
9
A polypill strategy to improve adherence: results from the FOCUS project.多药复方片策略提高依从性：FOCUS 项目结果。
J Am Coll Cardiol. 2014;64(20):2071-82. doi: 10.1016/j.jacc.2014.08.021. Epub 2014 Sep 1.
10
Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, A Randomized Clinical Trial.固定剂量复方疗法用于主要心血管事件的二级预防：文献综述及波斯复方药丸的设计，一项随机临床试验
Curr Probl Cardiol. 2022 Jun;47(6):100872. doi: 10.1016/j.cpcardiol.2021.100872. Epub 2021 Apr 20.
本文引用的文献
1
Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.固定剂量复方制剂（波利维）在心血管疾病一级和二级预防中的成本效益：系统文献回顾。
PLoS One. 2022 Jul 28;17(7):e0271908. doi: 10.1371/journal.pone.0271908. eCollection 2022.
Zotero 插件